Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 103

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 103
---
904

        $
        12.79

        6.72

        $
        —

        Options exercisable, December 31, 2024

        7,941,719

        $
        13.64

        6.09

        $
        —

        Options unvested, December 31, 2024

        2,942,185

        $
        10.48

        8.42

        $
        —

      The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common shares for those stock options that had an exercise price lower than the fair value of the Company’s common shares. The aggregate intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was nil and $0.5 million, respectively.The total fair value of options vested during the years ended December 31, 2024 and 2023 was $22.6 million and $24.4 million, respectively.During the year ended December 31, 2024, an aggregate of 8,612 options were exercised at a weighted-average exercise price of $1.99 per share, for aggregate proceeds of $0.02 million. As a result, an amount of $0.01 million previously included in additional paid-in-capital related to the exercised options has been credited to common shares and deducted from additional paid-in-capital. 

122

Restricted Share UnitsThe following table summarizes the Company’s restricted share unit activity:

        Number ofshares

        Weightedaveragegrant date fair value

        Weightedaverageremainingcontractualterm(in years)

        Intrinsic value (in thousands)

        Outstanding, January 1, 2024

        603,685

        $
        12.42

        2.09

        $
        4,407

        Awarded

        527,273

        $
        6.95

        Vested and released

        (200,262
        )
         
        $
        12.42

        Cancelled or forfeited

        (166,537
        )
         
        $
        9.80

        Outstanding, December 31, 2024

        764,159

        $
        9.22

        1.59

        $
        —

      The fair value of each restricted share unit is estimated on the date